GNH USA

Europe — EMA

Ovaleap (Follitropin Alfa (Genetical Recombination))

GNH USA supplies Ovaleap (Follitropin Alfa), a glycoprotein hormone for ovarian stimulation in assisted reproduction. Request a quote for global supply.

Follitropin Alfa (Genetical Recombination)

Request sourcing

1
Pack/s

What is Follitropin Alfa (Genetical Recombination)?

Follitropin alfa, the active ingredient in Ovaleap, is a glycoprotein hormone presented as a lyophilized powder for subcutaneous injection use. It stimulates follicular development in women undergoing assisted reproductive technology.\n\nGNH India supplies Ovaleap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Follitropin Alfa (Genetical Recombination) used for?

Ovaleap (follitropin alfa) is a recombinant follicle‑stimulating hormone used in assisted reproductive technology.\n\nControlled ovarian stimulation: promotes development of multiple follicles in women undergoing IVF.\nOvarian induction for intrauterine insemination: enhances follicular growth to improve IUI success.\nOvulation induction in anovulatory women: supports follicular maturation in patients with hypothalamic or pituitary dysfunction.

What are the side effects of Follitropin Alfa (Genetical Recombination)?

Common Side Effects:\n- Injection site reactions: redness, swelling or pain at the injection site.\n- Mild ovarian hyperstimulation syndrome: abdominal discomfort, bloating, mild weight gain.\n- Headache: mild to moderate intensity.\n- Nausea: occasional episodes.\n- Breast tenderness: mild discomfort.\n\nSerious or Rare Side Effects:\n- Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, pleural effusion, or ascites.\n- Thromboembolic events: rare blood clots that may occur with severe OHSS.\n- Allergic reactions: rash, urticaria, or anaphylaxis in hypersensitive individuals.

What precautions apply to Follitropin Alfa (Genetical Recombination)?

Before initiating Ovaleap, clinicians should consider several safety measures.\n\nPatient selection: assess ovarian reserve and risk of OHSS before initiating therapy.\nMonitoring: perform regular ultrasound and estradiol measurements during stimulation.\nContraindications: avoid in pregnancy, known hypersensitivity to FSH or any excipient.\nDrug interactions: review concomitant use of gonadotropin‑releasing hormone analogues.\nPregnancy: discontinue once pregnancy is confirmed.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Follitropin Alfa (Genetical Recombination) interact with?

Ovaleap may interact with other agents that affect ovarian response or coagulation.\n\nMajor Interactions (Avoid):\n- GnRH agonists (long‑acting): may cause excessive ovarian response when combined without proper protocol.\n- Clomiphene citrate: concurrent use can increase risk of ovarian hyperstimulation.\n- Exogenous estrogen therapy: may alter follicular response.\n\nModerate Interactions (Monitor Closely):\n- Anticoagulants (e.g., heparin): monitor for bleeding if OHSS occurs.\n- Thyroid hormone replacement: adjust dose as ovarian stimulation can affect thyroid function.\n- Corticosteroids: may mask symptoms of OHSS.

Frequently asked questions

What is Ovaleap used for?+
Ovaleap is a recombinant follicle‑stimulating hormone indicated for controlled ovarian stimulation in women undergoing assisted reproductive techniques such as in‑vitro fertilisation, intrauterine insemination, and ovulation induction for anovulatory infertility.
How does follitropin alfa work?+
Follitropin alfa mimics natural FSH by binding to FSH receptors on ovarian granulosa cells. This activates intracellular cAMP pathways, leading to estrogen production, granulosa cell proliferation, and the growth and maturation of ovarian follicles required for ovulation.
What is the usual dose of Ovaleap?+
The dose of Ovaleap is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian reserve, treatment protocol, and response to monitoring, and then provides a specific dosing regimen.
Is Ovaleap safe in pregnancy or breastfeeding?+
Ovaleap is not intended for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Limited data are available on breastfeeding; therefore, the product should be used only if the potential benefit outweighs any possible risk to the infant.
How do I order Ovaleap from GNH USA?+
To order Ovaleap, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and import documentation.
How does Ovaleap compare with other FSH products?+
Ovaleap is a recombinant FSH comparable to other brands such as Gonal‑F or Menopur in terms of biological activity. Differences may lie in manufacturing process, vial size, and excipients, but clinical efficacy and safety profiles are generally similar when used according to approved protocols.
What are the storage and handling requirements for Ovaleap?+
Ovaleap must be stored refrigerated between 2 °C and 8 °C. Keep the vials in the original carton, protect them from light, and do not freeze or shake. Once reconstituted, the solution should be used within the time frame specified in the product label and kept refrigerated.
How is Ovaleap administered?+
Ovaleap is supplied as a lyophilized powder for injection. After reconstitution with the provided diluent, the solution is administered subcutaneously, usually in the abdominal wall or thigh, according to the dosing schedule prescribed by the treating specialist.
What are the most serious risks to watch for with Ovaleap?+
The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and respiratory compromise, as well as rare thromboembolic events and severe allergic reactions such as anaphylaxis.
Who should not use Ovaleap?+
Ovaleap is contraindicated in women who are already pregnant, have known hypersensitivity to follitropin alfa or any excipient, have ovarian or estrogen‑dependent tumors, or have uncontrolled thyroid disease or severe ovarian cysts. Clinicians should evaluate each patient before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Follitropin Alfa (Genetical Recombination)
Route
Subcutaneous Use
Manufacturer
Theramex Ireland Limited
Origin
EU

Related products

Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU